MYMD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease...

Stats
Today's Volume	104 751
Average Volume	226 859
Market Cap	6.17M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.0230 (0.80%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-24	Rivard Paul	Buy	150 000	Common stock
2023-08-17	Rivard Paul	Buy	25 000	Common stock
2023-06-07	Chapman Christopher C Jr	Buy	300 000	Employee Stock Option (Right to Buy)
2023-06-07	Kaplin Adam	Buy	150 000	Employee Stock Option (Right to Buy)
2023-06-07	Uzonwanne Jude	Buy	150 000	Employee Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 84 transactions
Buy: 8 636 568 \| Sell: 532 775

Volume Correlation

Long: 0.12 (neutral)

Short: -0.64 (weak negative)

Signal:(52.21) Neutral

MyMD Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MyMD Pharmaceuticals, Correlation - Currency/Commodity

-0.58
( weak negative )

0.46
( neutral )

0.00
( neutral )

0.80
( moderate )

0.84
( strong )

MyMD Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.59

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.420

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$1.930

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.10

Financial Reports:

No articles found.

MyMD Pharmaceuticals,

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.